RCUS — Arcus Biosciences, Inc.

—
NYSE · Health Care · Pharmaceuticals · CIK 1724521 ·
Last close
$16.39
Market Cap
$2.36B
52W High
$31.74
52W Low
$16.33
ADV30
2,228,915
Next earnings
2026-11-04

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 9,000,000 — -131,000,000 -128,000,000 818,000,000 151,000,000 460,000,000
Jun 2026 41,000,000 — -96,000,000 -91,000,000 924,000,000 150,000,000 460,000,000
Mar 2026 17,000,000 — -134,000,000 -128,000,000 997,000,000 201,000,000 473,000,000
Dec 2025 33,000,000 — -114,000,000 -106,000,000 1,139,000,000 222,000,000 508,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-465,000,000
Investing CF
$66,000,000
Financing CF
$312,000,000
CapEx
$-2,000,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.63
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,832,000,000
Inventory
—
Receivables
$23,000,000
ST Investments
$479,000,000
EBIT TTM
$-442,000,000
Pretax Income TTM
$-453,000,000
Interest Exp TTM
$11,000,000
Analysts
12

Yahoo Snapshot (yfinance, live)

Total Revenue
$100,000,000
EBITDA
$-465,000,000
Free Cash Flow
$-274,750,016
Enterprise Value
$2,243,148,544
Total Cash
$630,000,000
Total Debt
$241,000,000
Shares Out
143,990,614
Trailing EPS
$-3.64
Book Value
$2.81
ROE
-114.1%
ROA
-33.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 247,000,000 -386,000,000 -353,000,000 1,139,000,000 508,000,000 631,000,000 -482,000,000
Dec 2024 258,000,000 -310,000,000 -283,000,000 1,150,000,000 665,000,000 485,000,000 -170,000,000
Dec 2023 117,000,000 -340,000,000 -307,000,000 1,095,000,000 633,000,000 462,000,000 -306,000,000
Dec 2022 112,000,000 -280,000,000 -267,000,000 1,345,000,000 688,000,000 657,000,000 438,000,000

TTM Snapshot

Revenues TTM
$117,000,000
NetIncome TTM
$-460,000,000
OpCashFlow TTM
—
Assets (Latest)
$924,000,000
Forward EPS
$-3.13

Max Pain — expiry 2026-12-18

max pain strike: $20.00 · spot: $15.76 · call oi: 1,158 · put oi: 1,359
Expected Move to 2026-12-18: ±$3.73 (23.64%) — implied range $12.04 – $19.49 · ATM straddle on $15.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NAMS NewAmsterdam Pharma Co N.V. $2.33B $19.39 —
GLPGF Lakefront Biotherapeutics NV $2.30B $35.15 —
PBH Prestige Consumer Healthcare Inc. $2.29B $48.22 —
PHVS Pharvaris N.V. $2.27B $32.28 —
LKFT Lakefront Biotherapeutics NV $2.25B $34.39 —

News headlines (Yahoo Finance, 1h cache)

Arcus Biosciences to Participate in Two Upcoming Investor Conferences
2026-11-18 21:05 · Yahoo
Caught Out By Arcus Biosciences' Slide? Here's What Bears Saw
2026-11-18 20:11 · Yahoo
Arcus Biosciences, Inc. (RCUS) Reports Q3 Loss, Lags Revenue Estimates
2026-11-04 23:45 · Yahoo
Arcus Biosciences Reports Third-Quarter 2026 Financial Results and Provides a Pipeline Update
2026-11-04 21:05 · Yahoo
Arcus Biosciences to Participate in the Jefferies Global Healthcare Conference 2026 in London
2026-11-02 21:05 · Yahoo
Arcus Biosciences Announces New Employment Inducement Grants
2026-10-26 20:35 · Yahoo
How Investors May Respond To Arcus Biosciences (RCUS) $250 Million Share Sale
2026-10-24 21:13 · Yahoo
Arcus Biosciences (RCUS) Stock Looks Stretched As Casdatifan Trial Data Impresses
2026-10-24 19:09 · Yahoo
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
2026-10-22 02:53 · Yahoo
Arcus Biosciences stock falls on public offering announcement
2026-10-21 22:32 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.